广泛性焦虑障碍的药物治疗:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入89项随机试验、25 441例成年门诊广泛性焦虑障碍患者,比较22种活性药物与安慰剂的疗效与可接受性。度洛西汀、普瑞巴林、文拉法辛和艾司西酞普兰疗效优于安慰剂且可接受性较好;喹硫平对HAM-A改善最大但耐受性差。初始药物治疗失败不应放弃药物治疗策略。
要点
- 度洛西汀、普瑞巴林、文拉法辛和艾司西酞普兰疗效优于安慰剂且可接受性较好。
- 喹硫平对HAM-A改善最大但耐受性差,帕罗西汀和苯二氮䓬类同样有效但耐受性差。
- 初始药物治疗失败不应放弃药物治疗策略,多类药物均有有效选择。
核心结论
- 广泛性焦虑障碍有多种跨类药物有效治疗选择,初始药物治疗失败不应放弃药物治疗策略。
研究设计与样本
- 系统综述与网络Meta分析纳入89项随机试验,共25 441例成年门诊广泛性焦虑障碍患者,随机分配至22种活性药物或安慰剂。
主要发现
- 度洛西汀MD -3·13(95%CrI -4·13至-2·13)、普瑞巴林MD -2·79(95%CrI -3·69至-1·91)、文拉法辛MD -2·69(95%CrI -3·50至-1·89)、艾司西酞普兰MD -2·45(95%CrI -3·27至-1·63)疗效优于安慰剂且可接受性较好。
- 米氮平、舍曲林、氟西汀、丁螺环酮和阿戈美拉汀也有效且耐受良好,但受小样本量限制。
- 喹硫平对HAM-A改善最大(MD -3·60,95%CrI -4·83至-2·39),但相比安慰剂耐受性差(OR 1·44,95%CrI 1·16-1·80)。
- 帕罗西汀和苯二氮䓬类有效但相比安慰剂耐受性差。
关键数值与推荐
- 主要结局为疗效(HAM-A评分变化均数差)和可接受性(任何原因的研究脱落)。
- 报告偏倚风险被认为低,尽可能纳入所有已完成研究以避免发表偏倚。
临床怎么用
- 可优先考虑度洛西汀、普瑞巴林、文拉法辛或艾司西酞普兰等疗效与可接受性较均衡的药物。
- 喹硫平、帕罗西汀和苯二氮䓬类虽有效但耐受性差,使用时需权衡。
- 初始药物治疗失败时不应放弃药物治疗策略,可考虑换用其他类别药物。
局限性
- 米氮平、舍曲林、氟西汀、丁螺环酮和阿戈美拉汀的发现受小样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalised anxiety disorder is a disease that can be associated with substantial dysfunction. Pharmacological treatment is often the first choice for clinicians because of the cost and resource constraints of psychological alternatives, but there is a paucity of comparative information for the multiple available drug choices. METHODS: A systematic review and network meta-analysis was performed on randomised trials in adult outpatients with generalised anxiety disorder identified from MEDLINE, Web of Science, Cochrane Library, ClinicalTrials.gov, Chinese National Knowledge Infrastructure (CNKI), Wanfang data, Drugs@FDA and commercial pharmaceutical registries. Placebo and active control trials were included. Data were extracted from all manuscripts and reports. Primary outcomes were efficacy (mean difference [MD] in change in Hamilton Anxiety Scale Score) and acceptability (study discontinuations for any cause). We estimated summary mean treatment differences and odds ratios using network meta-analyses with random effects. This study is registered with PROSPERO, number CRD42018087106. FINDINGS: Studies were published between Jan 1, 1994 and Aug 1, 2017, in which 1992 potential studies were screened for inclusion. This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo. Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability. Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes. Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo. Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo. Risk of reporting bias was considered low, and when possible all completed studies were included to avoid publication bias. INTERPRETATION: To our knowledge, this is the largest contemporary review of pharmacological agents for the treatment of generalised anxiety disorder by use of network analysis. There are several effective treatment choices for generalised anxiety disorder across classes of medication. The failure of initial pharmacological therapy might not be a reason to abandon a pharmacological treatment strategy. FUNDING: No funding was received for this research.
引用
- Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019. PMID: 30712879. doi:10.1016/S0140-6736(18)31793-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。